publication venue for
- Doravirine dose selection and 96-week safety and efficacy versus efavirenz in antiretroviral therapy-naive adults with HIV-1 infection in a Phase IIb trial. 2019
- Combined effect of sex and age in response to antiretroviral therapy in HIV-infected patients. 21-29. 2017
- Impact of prior virologic failure and nucleos(t)ide genotypic resistance mutations on the efficacy of switching from ritonavir-boosted protease inhibitors to raltegravir. 1-20. 2014
- Relevant gender differences in epidemiological profile, exposure to first antiretroviral regimen and survival in the Spanish AIDS Research Network Cohort.. 375-385. 2014
- Persistence of novel first-line antiretroviral regimes in a cohort of HIV-positive subjects, CoRIS 2008-2010. 161-170. 2013
- Persistence of novel first-line antiretroviral regimes in a cohort of HIV-positive subjects, CoRIS 2008-2010. Persistence of novel first-line antiretroviral regimes in a cohort of HIV-positive subjects, CoRIS 2008-2010. . 161-170. 2013
- Educational gradient in HIV diagnosis delay, mortality, antiretroviral treatment initiation and response in a country with universal health care. 1-8. 2012
- Evolution of HIV-1 genotype in plasma RNA and peripheral blood mononuclear cells proviral DNA after interruption and resumption of antiretroviral therapy. 577-583. 2012
- Short-term and long-term clinical and immunological consequences of stopping antiretroviral therapy in HIV-infected patients with preserved immune function 2012
- Endothelial function is impaired in HIV-infected patients with lipodystrophy. . 101-110. 2010
- Evolution of transmitted HIV-1 with drug-resistance mutations in the absence of therapy: effects on CD4+ T-cell count and HIV-1 RNA load. 173-178. 2006
- Changes in body fat composition after 1 year of salvage therapy with lopinavir/ritonavir-containing regimens and its relationship with lopinavir plasma concentrations. 105-113. 2004